2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Journal of the American College of Cardiology

Volumn 68, Issue 10, 2016, Pages 1082-1115

  Levine, Glenn N ^a   Bates, Eric R ^a   Bittl, John A ^a   Brindis, Ralph G ^a   Fihn, Stephan D ^a   Fleisher, Lee A ^a   Granger, Christopher B ^a   Lange, Richard A ^a   Mack, Michael J ^a   Mauri, Laura ^a   Mehran, Roxana ^a   Mukherjee, Debabrata ^a   Newby, L Kristin ^a   O'Gara, Patrick T ^a   Sabatine, Marc S ^a   Smith, Peter K ^a   Smith, Sidney C ^a  

^a NONE

Author keywords

ACC AHA Clinical Practice Guideline; acute coronary syndrome; aspirin; coronary artery disease; coronary stents; dual antiplatelet therapy (DAPT); focused update; P2Y 12 inhibitor; stable ischemic heart disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; PROTON PUMP INHIBITOR; PURINERGIC P2Y12 RECEPTOR BLOCKING AGENT; PURINERGIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; BLOOD CLOTTING PARAMETERS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; DUAL ANTIPLATELET THERAPY; ELECTIVE SURGERY; GENETIC SCREENING; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; PERCUTANEOUS CORONARY INTERVENTION; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; ALGORITHM; TIME FACTOR;

ALGORITHMS; ASPIRIN; CORONARY ARTERY DISEASE; HUMANS; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TIME FACTORS;

EID: 84994777362     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.03.513     Document Type: Article

References (163)

1. 1 ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines. Available at: http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf and http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf. American College of Cardiology and American Heart Association. Accessed January 23, 2015.
2. 2 Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Institute of Medicine (US). Clinical Practice Guidelines We Can Trust. 2011, National Academies Press, Washington, DC.
3. 3 Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Institute of Medicine (US). Finding What Works in Health Care: Standards for Systematic Reviews. 2011, National Academies Press, Washington, DC.
4. 4 Anderson, J.L., Heidenreich, P.A., Barnett, P.G., et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2304–2322.
5. 5 Arnett, D.K., Goodman, R.A., Halperin, J.L., et al. AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and U.S. Department of Health and Human Services. J Am Coll Cardiol 64 (2014), 1851–1856.
6. 6 Jacobs, A.K., Kushner, F.G., Ettinger, S.M., et al. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61 (2013), 213–265.
7. 7 Jacobs, A.K., Anderson, J.L., Halperin, J.L., The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 64 (2014), 1373–1384.
8. 8 Halperin, J.L., Levine, G.N., Al-Khatib, S.M., et al. Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 67 (2016), 1572–1574.
9. 9 Levine, G.N., Bates, E.R., Blankenship, J.C., et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58 (2011), e44–e122.
10. 10 Hillis, L.D., Smith, P.K., Anderson, J.L., et al., 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol 58 (2011), e123–e210.
11. 11 Fihn, S.D., Blankenship, J.C., Alexander, K.P., et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 64 (2014), 1929–1949.
12. 12 Fihn, S.D., Gardin, J.M., Abrams, J., et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 60 (2012), 2564–2603.
13. 13 O'Gara, P.T., Kushner, F.G., Ascheim, D.D., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61 (2013), e78–e140.
14. 14 Amsterdam, E.A., Wenger, N.K., Brindis, R.G., et al. 2014 AHA/ACC guideline for the management of patients with non—ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 64 (2014), e139–e228.
15. 15 Fleisher, L.A., Fleischmann, K.E., Auerbach, A.D., et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 64 (2014), e77–e137.
16. 16 Mauri, L., Kereiakes, D.J., Yeh, R.W., et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371 (2014), 2155–2166.
17. 17 Colombo, A., Chieffo, A., Frasheri, A., et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol 64 (2014), 2086–2097.
18. 18 Gwon, H.-C., Hahn, J.-Y., Park, K.W., et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 125 (2012), 505–513.
19. 19 Kim, B.-K., Hong, M.-K., Shin, D.-H., et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 60 (2012), 1340–1348.
20. 20 Feres, F., Costa, R.A., Abizaid, A., et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 310 (2013), 2510–2522.
21. 21 Schulz-Schüpke, S., Byrne, R.A., Ten Berg, J.M., et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 36 (2015), 1252–1263.
22. 22 Park, S.-J., Park, D.-W., Kim, Y.-H., et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 362 (2010), 1374–1382.
23. 23 Valgimigli, M., Campo, G., Monti, M., et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 125 (2012), 2015–2026.
24. 24 Collet, J.-P., Silvain, J., Barthélémy, O., et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 384 (2014), 1577–1585.
25. 25 Gilard, M., Barragan, P., Noryani, A.A.L., et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol 65 (2015), 777–786.
26. 26 Lee, C.W., Ahn, J.-M., Park, D.-W., et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation 129 (2014), 304–312.
27. 27 Helft, G., Steg, P.G., Le Feuvre, C., et al. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. Eur Heart J 37 (2016), 365–374.
28. 28 Bonaca, M.P., Bhatt, D.L., Cohen, M., et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372 (2015), 1791–1800.
29. 29 Roffi, M., Patrono, C., Collet, J.-P., et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 37 (2016), 267–315.
30. 30 Bittl, J.A., Baber, U., Bradley, S.M., Wijeysundera, D.N., Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol, 2016 Mar 22 [E-pub ahead of print].
31. 31 Steg, P.G., James, S.K., Atar, D., et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33 (2012), 2569–2619.
32. 32 Wijns, W., Kolh, P., Danchin, N., et al. Guidelines on myocardial revascularization. Eur Heart J 31 (2010), 2501–2555.
33. 33 Hamm, C.W., Bassand, J.-P., Agewall, S., et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the Management of Acute Coronary Syndromes (ACS) in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 32 (2011), 2999–3054.
34. 34 Palmerini, T., Sangiorgi, D., Valgimigli, M., et al. Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. J Am Coll Cardiol 65 (2015), 1092–1102.
35. 35 Palmerini, T., Benedetto, U., Bacchi-Reggiani, L., et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 385 (2015), 2371–2382.
36. 36 Giustino, G., Baber, U., Sartori, S., et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 65 (2015), 1298–1310.
37. 37 Navarese, E.P., Andreotti, F., Schulze, V., et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ, 350, 2015, h1618.
38. 38 Navarese, E.P., Tandjung, K., Claessen, B., et al. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ, 347, 2013, f6530.
39. 39 Hermiller, J.B., Krucoff, M.W., Kereiakes, D.J., et al. Benefits and risks of extended dual antiplatelet therapy after everolimus-eluting stents. J Am Coll Cardiol Intv 9 (2016), 138–147.
40. 40 Bhatt, D.L., Fox, K.A.A., Hacke, W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006), 1706–1717.
41. 41 Bhatt, D.L., Flather, M.D., Hacke, W., et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49 (2007), 1982–1988.
42. 12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J 37 (2016), 1133–1142.
43. 43 Yeh, R.W., Kereiakes, D.J., Steg, P.G., et al. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol 65 (2015), 2211–2221.
44. 44 Udell, J.A., Bonaca, M.P., Collet, J.-P., et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J 37 (2016), 390–399.
45. 45 Mauri, L., Elmariah, S., Yeh, R.W., et al. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J 37 (2016), 378–385.
46. 46 Spencer, F.A., Prasad, M., Vandvik, P.O., et al. Longer versus shorter-duration dual-antiplatelet therapy after drug-eluting stent placement: a systematic review and meta-analysis. Ann Intern Med 163 (2015), 118–126.
47. 47 Montalescot, G., Brieger, D., Dalby, A.J., et al. Duration of dual antiplatelet therapy after coronary stenting: a review of the evidence. J Am Coll Cardiol 66 (2015), 832–847.
48. 48 Elmariah, S., Mauri, L., Doros, G., et al. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet 385 (2015), 792–798.
49. 49 U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA review finds long-term treatment with blood-thinning medicine Plavix (clopidogrel) does not change risk of death. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm471286.htm. Published November 6, 2015; updated December 9, 2015 accessed February 17, 2016.
50. 50 Steinhubl, S.R., Berger, P.B., Mann, J.T. 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002), 2411–2420.
51. 51 Mehta, S.R., Yusuf, S., Peters, R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001), 527–533.
52. 52 Yusuf, S., Zhao, F., Mehta, S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001), 494–502.
53. 53 Wallentin, L., Becker, R.C., Budaj, A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 (2009), 1045–1057.
54. 54 Wiviott, S.D., Braunwald, E., McCabe, C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007), 2001–2015.
55. 55 Montalescot, G., Wiviott, S.D., Braunwald, E., et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373 (2009), 723–731.
56. 56 Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002), 71–86.
57. 57 Patrono, C., Baigent, C., Hirsh, J., et al. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (2008), 199S–233S.
58. 58 Peters, R.J.G., Mehta, S.R., Fox, K.A.A., et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 108 (2003), 1682–1687.
59. 59 Steinhubl, S.R., Bhatt, D.L., Brennan, D.M., et al. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med 150 (2009), 379–386.
60. 60 Mehta, S.R., Tanguay, J.-F., Eikelboom, J.W., et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376 (2010), 1233–1243.
61. 61 Yeh RW, Secemsky E, Kereiakes DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond one year after percutaneous coronary intervention: an analysis from the randomized Dual Antiplatelet Therapy Study. JAMA. In Press.
62. 62 Califf, R.M., Armstrong, P.W., Carver, J.R., et al. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. J Am Coll Cardiol 27 (1996), 1007–1019.
63. 63 Sachdev, M., Sun, J.L., Tsiatis, A.A., et al. The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease. J Am Coll Cardiol 43 (2004), 576–582.
64. 64 Binder, R.K., Lüscher, T.F., O'Connor, S.A., Duration of dual antiplatelet therapy after coronary artery stenting: where is the sweet spot between ischaemia and bleeding?. Eur Heart J 36 (2015), 1207–1211.
65. 65 Subherwal, S., Bach, R.G., Chen, A.Y., et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation 119 (2009), 1873–1882.
66. 66 Moscucci, M., Fox, K.A., Cannon, C.P., et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 24 (2003), 1815–1823.
67. 67 Mehran, R., Pocock, S.J., Nikolsky, E., et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 55 (2010), 2556–2566.
68. 68 Baber, U., Mehran, R., Sharma, S.K., et al. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol 58 (2011), 1569–1577.
69. 69 Cayla, G., Hulot, J.-S., O'Connor, S.A., et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA 306 (2011), 1765–1774.
70. 70 Campo, G., Tebaldi, M., Vranckx, P., et al. Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia). J Am Coll Cardiol 63 (2014), 506–512.
71. 71 James, S.K., Roe, M.T., Cannon, C.P., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ, 342, 2011, d3527.
72. 72 Steg, P.G., James, S., Harrington, R.A., et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 122 (2010), 2131–2141.
73. 73 US Food and Drug Administration. Medical Device Reporting (MDR). Available at: http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm. Updated July 16, 2015; accessed February 17, 2016.
74. 74 Abraham, N.S., Hlatky, M.A., Antman, E.M., et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 56 (2010), 2051–2066.
75. 75 Serebruany, V.L., Steinhubl, S.R., Berger, P.B., et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 95 (2005), 1218–1222.
76. 76 Jolly, S.S., Pogue, J., Haladyn, K., et al. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. Eur Heart J 30 (2009), 900–907.
77. 77 Lorenz, R.L., Schacky, C.V., Weber, M., et al. Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily): effects on platelet aggregation and thromboxane formation. Lancet 1 (1984), 1261–1264.
78. 78 Xian, Y., Wang, T.Y., McCoy, L.A., et al. Association of discharge aspirin dose with outcomes after acute myocardial infarction: insights from the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. Circulation 132 (2015), 174–181.
79. 79 Montalescot, G., Drobinski, G., Maclouf, J., et al. Evaluation of thromboxane production and complement activation during myocardial ischemia in patients with angina pectoris. Circulation 84 (1991), 2054–2062.
80. 80 Patrono, C., Ciabattoni, G., Patrignani, P., et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72 (1985), 1177–1184.
81. 81 Steinhubl, S.R., Berger, P.B., Aspirin following PCI: too much of a good thing?. Eur Heart J 30 (2009), 882–884.
82. 82 Mahaffey, K.W., Wojdyla, D.M., Carroll, K., et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 124 (2011), 544–554.
83. 83 National Patient-Centered Clinical Research Network. ADAPTABLE, the Aspirin Study - A Patient-Centered Trial. Available at: http://theaspirinstudy.org. Accessed February 17, 2016.
84. 84 Dans, A.L., Connolly, S.J., Wallentin, L., et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 127 (2013), 634–640.
85. 85 Faxon, D.P., Eikelboom, J.W., Berger, P.B., et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North-American perspective. Thromb Haemost 106 (2011), 572–584.
86. 86 Hansen, M.L., Srensen, R., Clausen, M.T., et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 170 (2010), 1433–1441.
87. 87 Sørensen, R., Hansen, M.L., Abildstrom, S.Z., et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 374 (2009), 1967–1974.
88. 88 Lip, G.Y.H., Windecker, S., Huber, K., et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA). Eur Heart J 35 (2014), 3155–3179.
89. 89 Dewilde, W.J.M., Oirbans, T., Verheugt, F.W.A., et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381 (2013), 1107–1115.
90. 90 Fiedler, K.A., Maeng, M., Mehilli, J., et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE Trial. J Am Coll Cardiol 65 (2015), 1619–1629.
91. 91 Dewilde, W.J.M., Janssen, P.W.A., Verheugt, F.W.A., et al. Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary review. J Am Coll Cardiol 64 (2014), 1270–1280.
92. 92 Moser, M., Olivier, C.B., Bode, C., Triple antithrombotic therapy in cardiac patients: more questions than answers. Eur Heart J 35 (2014), 216–223.
93. 93 Capodanno, D., Angiolillo, D.J., Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. Circ Cardiovasc Interv 7 (2014), 113–124.
94. 94 Leon, M.B., Baim, D.S., Popma, J.J., et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339 (1998), 1665–1671.
95. 95 Schömig, A., Neumann, F.J., Kastrati, A., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334 (1996), 1084–1089.
96. 96 Brar, S.S., Kim, J., Brar, S.K., et al. Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. J Am Coll Cardiol 51 (2008), 2220–2227.
97. 97 Eisenstein, E.L., Anstrom, K.J., Kong, D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007), 159–168.
98. 98 Sabatine, M.S., Cannon, C.P., Gibson, C.M., et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294 (2005), 1224–1232.
99. 99 Cutlip, D.E., Baim, D.S., Ho, K.K., et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 103 (2001), 1967–1971.
100. 100 Wilson, S.H., Rihal, C.S., Bell, M.R., et al. Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin. Am J Cardiol 83 (1999), 1006–1011.
101. 101 Kaluza, G.L., Joseph, J., Lee, J.R., et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 35 (2000), 1288–1294.
102. 102 Wilson, S.H., Fasseas, P., Orford, J.L., et al. Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol 42 (2003), 234–240.
103. 103 Nuttall, G.A., Brown, M.J., Stombaugh, J.W., et al. Time and cardiac risk of surgery after bare-metal stent percutaneous coronary intervention. Anesthesiology 109 (2008), 588–595.
104. 104 Grines, C.L., Bonow, R.O., Casey, D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115 (2007), 813–818.
105. 105 Pfisterer, M., Brunner-La Rocca, H.P., Buser, P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006), 2584–2591.
106. 106 Navarese, E.P., Kowalewski, M., Kandzari, D., et al. First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients. Open Heart, 1, 2014, e000064.
107. 107 Palmerini, T., Kirtane, A.J., Serruys, P.W., et al. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv 5 (2012), 357–364.
108. 108 Räber, L., Magro, M., Stefanini, G.G., et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 125 (2012), 1110–1121.
109. 109 Sarno, G., Lagerqvist, B., Nilsson, J., et al. Stent thrombosis in new-generation drug-eluting stents in patients with STEMI undergoing primary PCI: a report from SCAAR. J Am Coll Cardiol 64 (2014), 16–24.
110. 110 Kočka, V., Malý, M., Toušek, P., et al. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study “Prague 19”. Eur Heart J 35 (2014), 787–794.
111. 111 Kereiakes, D.J., Meredith, I.T., Windecker, S., et al. Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II Randomized Trial. Circ Cardiovasc Interv, 8, 2015, e002372.
112. 112 Puricel, S., Arroyo, D., Corpataux, N., et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol 65 (2015), 791–801.
113. 113 Gao, R., Yang, Y., Han, Y., et al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China Trial. J Am Coll Cardiol 66 (2015), 2298–2309.
114. 114 Windecker, S., Serruys, P.W., Wandel, S., et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 372 (2008), 1163–1173.
115. 115 Meredith, I.T., Verheye, S., Dubois, C.L., et al. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. J Am Coll Cardiol 59 (2012), 1362–1370.
116. 116 Ellis, S.G., Kereiakes, D.J., Metzger, D.C., et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med 373 (2015), 1905–1915.
117. 117 Urban, P., Meredith, I.T., Abizaid, A., et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med 373 (2015), 2038–2047.
118. 118 Fox, K.A.A., Mehta, S.R., Peters, R., et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non—ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 110 (2004), 1202–1208.
119. 119 Kim, D.H., Daskalakis, C., Silvestry, S.C., et al. Aspirin and clopidogrel use in the early postoperative period following on-pump and off-pump coronary artery bypass grafting. J Thorac Cardiovasc Surg 138 (2009), 1377–1384.
120. 120 Sørensen, R., Abildstrøm, S.Z., Hansen, P.R., et al. Efficacy of post-operative clopidogrel treatment in patients revascularized with coronary artery bypass grafting after myocardial infarction. J Am Coll Cardiol 57 (2011), 1202–1209.
121. 121 Gao, G., Zheng, Z., Pi, Y., et al. Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial. J Am Coll Cardiol 56 (2010), 1639–1643.
122. 122 Deo, S.V., Dunlay, S.M., Shah, I.K., et al. Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis. J Card Surg 28 (2013), 109–116.
123. 123 Nocerino, A.G., Achenbach, S., Taylor, A.J., Meta-analysis of effect of single versus dual antiplatelet therapy on early patency of bypass conduits after coronary artery bypass grafting. Am J Cardiol 112 (2013), 1576–1579.
124. 124 Ibrahim, K., Tjomsland, O., Halvorsen, D., et al. Effect of clopidogrel on midterm graft patency following off-pump coronary revascularization surgery. Heart Surg Forum 9 (2006), E581–E856.
125. 125 Mannacio, V.A., Di Tommaso, L., Antignan, A., et al. Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study. Heart 98 (2012), 1710–1715.
126. 126 Farooq, V., Serruys, P.W., Bourantas, C., et al. Incidence and multivariable correlates of long-term mortality in patients treated with surgical or percutaneous revascularization in the Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) trial. Eur Heart J 33 (2012), 3105–3113.
127. 127 Johnson, W.D., Kayser, K.L., Hartz, A.J., et al. Aspirin use and survival after coronary bypass surgery. Am Heart J 123 (1992), 603–608.
128. 128 Chesebro, J.H., Clements, I.P., Fuster, V., et al. A platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med 307 (1982), 73–78.
129. 129 Chesebro, J.H., Fuster, V., Elveback, L.R., et al. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med 310 (1984), 209–214.
130. 130 Goldman, S., Copeland, J., Moritz, T., et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 77 (1988), 1324–1332.
131. 131 Ebrahimi, R., Bakaeen, F.G., Uberoi, A., et al. Effect of clopidogrel use post coronary artery bypass surgery on graft patency. Ann Thorac Surg 97 (2014), 15–21.
132. 132 Kulik, A., Le May, M.R., Voisine, P., et al. Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the Clopidogrel After Surgery for Coronary Artery Disease (CASCADE) Trial. Circulation 122 (2010), 2680–2687.
133. 133 Gao, C., Ren, C., Li, D., et al. Clopidogrel and aspirin versus clopidogrel alone on graft patency after coronary artery bypass grafting. Ann Thorac Surg 88 (2009), 59–62.
134. 134 Sun, J.C.J., Teoh, K.H.T., Lamy, A., et al. Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study. Am Heart J 160 (2010), 1178–1184.
135. 135 de Leon, N., Jackevicius, C.A., Use of aspirin and clopidogrel after coronary artery bypass graft surgery. Ann Pharmacother 46 (2012), 678–687.
136. 136 Gurbuz, A.T., Zia, A.A., Vuran, A.C., et al. Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study. Eur J Cardiothorac Surg 29 (2006), 190–195.
137. 137 Smith, P.K., Goodnough, L.T., Levy, J.H., et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol 60 (2012), 388–396.
138. 138 Held, C., Asenblad, N., Bassand, J.P., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 57 (2011), 672–684.
139. 139 Varenhorst, C., Alstrom, U., Scirica, B.M., et al. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol 60 (2012), 1623–1630.
140. 140 Chen, Z.M., Jiang, L.X., Chen, Y.P., et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005), 1607–1621.
141. 141 Roe, M.T., Armstrong, P.W., Fox, K.A.A., et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 367 (2012), 1297–1309.
142. 142 Sabatine, M.S., Cannon, C.P., Gibson, C.M., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005), 1179–1189.
143. 143 Wijeysundera, D.N., Wijeysundera, H.C., Yun, L., et al. Risk of elective major noncardiac surgery after coronary stent insertion: a population-based study. Circulation 126 (2012), 1355–1362.
144. 144 Berger, P.B., Kleiman, N.S., Pencina, M.J., et al. Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry. J Am Coll Cardiol Intv 3 (2010), 920–927.
145. 145 Mehran, R., Baber, U., Steg, P.G., et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 382 (2013), 1714–1722.
146. 146 Holcomb, C.N., Hollis, R.H., Graham, L.A., et al. Association of coronary stent indication with postoperative outcomes following noncardiac surgery. JAMA Surg, 2015, 1–8.
147. 12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: a systematic review and meta-analysis. Eur Heart J Acute Cardiovasc Care. 2015 May 5 [E-pub ahead of print].
148. 148 Chee, Y.L., Crawford, J.C., Watson, H.G., et al. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. British Committee for Standards in Haematology. Br J Haematol 140 (2008), 496–504.
149. 149 van Werkum, J.W., Heestermans, A.A., Zomer, A.C., et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 53 (2009), 1399–1409.
150. 150 Secemsky, E.A., Matteau, A., Yeh, R.W., et al. Comparison of short- and long-term cardiac mortality in early versus late stent thrombosis (from Pooled PROTECT Trials). Am J Cardiol 115 (2015), 1678–1684.
151. 151 Holcomb, C.N., Graham, L.A., Richman, J.S., et al. The incremental risk of noncardiac surgery on adverse cardiac events following coronary stenting. J Am Coll Cardiol 64 (2014), 2730–2739.
152. 152 Cruden, N.L.M., Harding, S.A., Flapan, A.D., et al. Previous coronary stent implantation and cardiac events in patients undergoing noncardiac surgery. Circ Cardiovasc Interv 3 (2010), 236–242.
153. 153 Hawn, M.T., Graham, L.A., Richman, J.S., et al. Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. JAMA 310 (2013), 1462–1472.
154. 154 Rajagopalan, S., Ford, I., Bachoo, P., et al. Platelet activation, myocardial ischemic events and postoperative non-response to aspirin in patients undergoing major vascular surgery. J Thromb Haemost 5 (2007), 2028–2035.
155. 155 Diamantis, T., Tsiminikakis, N., Skordylaki, A., et al. Alterations of hemostasis after laparoscopic and open surgery. Hematology 12 (2007), 561–570.
156. 156 Fleisher, L.A., Beckman, J.A., Brown, K.A., et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll Cardiol 50 (2007), e159–e241.
157. 157 Oscarsson, A., Gupta, A., Fredrikson, M., et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth 104 (2010), 305–312.
158. 158 Burger, W., Chemnitius, J.-M., Kneissl, G.D., et al. Low-dose aspirin for secondary cardiovascular prevention–cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation–review and meta-analysis. J Intern Med 257 (2005), 399–414.
159. 159 Alshawabkeh, L.I., Prasad, A., Lenkovsky, F., et al. Outcomes of a preoperative “bridging” strategy with glycoprotein IIb/IIIa inhibitors to prevent perioperative stent thrombosis in patients with drug-eluting stents who undergo surgery necessitating interruption of thienopyridine administration. EuroIntervention 9 (2013), 204–211.
160. 160 Angiolillo, D.J., Firstenberg, M.S., Price, M.J., et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 307 (2012), 265–274.
161. 161 Savonitto, S., D'Urbano, M., Caracciolo, M., et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of “bridging” antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth 104 (2010), 285–291.
162. 162 Savonitto, S., Caracciolo, M., Cattaneo, M., et al. Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery. J Thromb Haemost 9 (2011), 2133–2142.
163. 163 Warshauer, J., Patel, V.G., Christopoulos, G., et al. Outcomes of preoperative bridging therapy for patients undergoing surgery after coronary stent implantation: a weighted meta-analysis of 280 patients from eight studies. Catheter Cardiovasc Interv 85 (2015), 25–31.